Navigation Links
Avantra Biosciences Offers Its Proprietary PATH® Slides for Sale
Date:3/22/2011

WOBURN, Mass., March 22, 2011 /PRNewswire/ -- Avantra Biosciences has announced they are selling their new and improved proprietary PATH® Protein Microarray Ultra-thin Nitrocellulose Slides. Additionally, Avantra is discussing the possibility of partnering with certain parties to expand the distribution network for the PATH slides.

The PATH Slide is the first protein microarray slide to provide the many benefits of nitrocellulose in a thin film that allows very low background fluorescence and excellent signal-to-noise ratio.

"Nitrocellulose has proven to be the protein-assay substrate of choice for decades. With this technology, researchers can use a wide variety of fluorescence probes to make protein assays easier, faster and more sensitive than ever before," said Brendan McKernan, President of Avantra Biosciences. "By delivering a high signal-to-noise ratio and low background fluorescence, we believe the PATH surface chemistry to be far superior to other commercially available protein-array surfaces."

Key Features:

  • Excellent stability and shelf life

  • Best in class sensitivity, accuracy, and reproducibility and dynamic range providing excellent spot morphology, retained protein conformation and functional activity.

  • Low background and increased dynamic range – proprietary ultra-thin nitrocellulose provides enhances signal-to-noise ratios

  • Standard slide format – adaptable to all commonly used slide format microarray readers

Ordering information
Email: sales@avantrabio.com
Phone: 877.395.7608
Fax: 617.892.7191

About Avantra Biosciences Corporation

Avantra Biosciences is a privately held diagnostics company that has pioneered next generation technology for protein biomarker analysis.  The PATH technology is integrated into the Avantra Q400 Biomarker Workstation.  Avantra's integrated system enables scientists and clinicians to perform multiplex biomarker analysis for research use only (RUO) from their lab bench or clinical trial site.

www.AvantraBio.com

Copyright © 2011 Avantra Biosciences Corporation. All rights reserved.


'/>"/>
SOURCE Avantra Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Ardea Biosciences Reports Recent Accomplishments and Announces Fourth Quarter and Full-Year 2010 Financial Results
2. Neurocrine Biosciences to Present at the Cowen & Co. 31st Annual Health Care Conference
3. Ardea Biosciences Announces Exercise in Full of Overallotment Option for Common Stock Offering
4. Swift Biosciences Presents Highly Sensitive, Highly Specific qPCR Mutation Detection Data at 18th International Molecular Medicine Tri-Conference
5. Martek Biosciences Inducted into Small Business Innovation Research (SBIR) Hall of Fame
6. Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results
7. YM BioSciences Reports Fiscal Second Quarter 2011 Operational and Financial Results
8. Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results
9. Sangamo BioSciences Announces Fourth Quarter and Full Year 2010 Conference Call and Webcast
10. YM BioSciences Announces Data from Nimotuzumab Phase II Gastric Cancer Trial Reported at ASCO GI Symposium
11. Ardea Biosciences Prices Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... , March 22, 2017 Good Start Genetics, ... has eclipsed the 130 million covered lives mark through ... of Texas . With newly signed ... continues to enjoy strong payor acceptance based on the ... programs and genetic counseling, its industry-leading customer care and ...
(Date:3/22/2017)... Mass. , March 22, 2017   iSpecimen ... today announced that Doctors Pathology Service (DPS), ... region of the United States , ... Delaware Health Information Network (DHIN) to make ... The novel program, announced in 2015 ...
(Date:3/22/2017)... , March 22, 2017 MarketNewsUpdates.com News ... ... conditions are being pressured as of late due to the ... pain management has a dramatic impact on patient,s quality of ... development activities for identifying new forms of opioid formulations that ...
(Date:3/22/2017)... 22, 2017   Boston Biomedical , an industry ... to target cancer stemness pathways, today announced its Board ... as Chief Executive Officer, effective April 24, 2017. ... Li , M.D., FACP, who has led Boston Biomedical ... his leadership, Boston Biomedical has grown from a "garage ...
Breaking Biology Technology:
(Date:3/2/2017)... Australian stem cell and regenerative medicine company, ... an agreement with the Monash Lung Biology Network, a ... and Department of Pharmacology at Monash University, ... to support the use of Cymerus™ mesenchymal stem cells ... Asthma is a chronic, long term lung condition recognised ...
(Date:2/28/2017)... -- News solutions for biometrics, bag drop and New ... At ... 16 March, Materna will present its complete end-to-end passenger journey, ... a real benefit for passengers. To accelerate the whole passenger ... point solutions to take passengers through the complete integrated process ...
(Date:2/26/2017)... 25, 2017  Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring, announces the ... "Too often, too many offenders return ... jails are trying to tackle this ongoing problem ... and family members. While significant steps are underway, Securus ...
Breaking Biology News(10 mins):